BioCentury
ARTICLE | Company News

IMMU receives payment from Amgen

February 1, 2001 8:00 AM UTC

Immunomedics (IMMU) received an $18 million upfront payment from partner AMGN under the companies' December deal for AMGN to develop and market in North America and Australia IMMU's epratuzumab humani...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article